Prior to the COVID-19 pandemic, there was strong evidence that TGF-β1 is a key driver in the pathophysiology of the acute respiratory distress syndrome (ARDS) and in chronic fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.